Skip to main content

Advertisement

Table 2 Summary of the AE profile for the integrated clinical studies

From: Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma

AE (preferred term), n (%) Placebo (n = 858) FF 50 μg OD (n = 338) FF 100 μg OD (n = 1663) FF 200 μg OD (n = 608) FP 100 μg BD (n = 217) FP 250 μg BD (n = 214) FP 500 μg BD (n = 305)
Any AE 278 (32) 121 (36) 912 (55) 256 (42) 94 (43) 90 (42) 136 (45)
Any drug-related AE 22 (3) 8 (2) 103 (6) 36 (6) 10 (5) 18 (8) 24 (8)
Any SAE 7 (<1) 1 (<1) 38 (2) 7 (1) 3 (1) 1 (<1) 4 (1)
Any drug-related SAE 0 0 3 (<1) 0 0 0 1 (<1)
Any AE leading to discontinuation of study drug 8 (<1) 2 (<1) 28 (2) 10 (2) 4 (2) 4 (2) 6 (2)
Deaths 0 0 2 (<1)a 0 0 0 0
  1. AE adverse event, BD twice daily, FF fluticasone furoate, OD once daily, FP fluticasone propionate, SAE serious adverse event
  2. aNeither death was determined by the investigator to be related to study medication